[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Korea University Anam Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":639},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,45,77,110,143,164,195,223,249,274,299,327,347,367,390,411,430,451,477,500,524,551,571,592,613],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642637","prediction-of-myocardial-injury-after-non-cardiac-surgery-in-urologic-cancer-patients-100642637",false,"NCT07634666","Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients","Prediction of Myocardial Injury After Major Non-Cardiac Surgery in Patients With Urologic Cancer: A Prospective Multicenter Observational Study","URO-MINS","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy)\n* Patients who undergo preoperative standard 12-lead electrocardiography\n* Patients classified as having intermediate or higher surgical risk\n* Patients who can be followed for at least 30 days postoperatively\n* Patients who voluntarily provide written informed consent to participate in this study\n\nExclusion Criteria:\n\n* History of major adverse cardiovascular events (MACE) within 6 months prior to surgery\n* Inability to obtain essential clinical information required for study participation and follow-up\n* Patients who are not hospitalized after surgery\n* Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons","ALL","60 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.",[25,26,27],"Myocardial Injury After Non-cardiac Surgery","Urologic Cancer","Major Adverse Cardiovascular Events (MACE)",[29,30,25,31,32,26],"Artificial Intelligence","Electrocardiography","Major Adverse Cardiovascular Events","Perioperative Cardiovascular Risk","NOT_YET_RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":21},"2026-06-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Korea University Anam Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100628738","cart-bp-pro-guided-blood-pressure-management-for-uncontrolled-hypertension-100628738","NCT07465549","CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension","Efficacy and Safety of Cuffless Ambulatory Blood Pressure Monitoring Device-Guided Blood Pressure Management Compared With Usual Care in Korean Patients With Uncontrolled Hypertension: A Multicenter Prospective Randomized Controlled Trial","CART-BP RCT","Inclusion Criteria:\n\n1. Age ≥ 19 years\n2. Uncontrolled hypertension defined as office systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg\n3. Ability and willingness to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. History of intolerance or contraindication to olmesartan, amlodipine, or hydrochlorothiazide\n2. Suspected secondary hypertension\n3. Atrial fibrillation\n4. Pregnancy or lactation\n5. Any serious medical condition that may interfere with study participation or interpretation of study results","19 Years",{"count":55,"type":21},400,"INTERVENTIONAL",[58],"NA","This multicenter, prospective, open-label randomized controlled trial evaluates the efficacy and safety of CART BP Pro-guided blood pressure management in Korean patients with uncontrolled hypertension. CART BP Pro is a wearable cuffless blood pressure monitoring device based on photoplethysmography technology that enables continuous ambulatory blood pressure monitoring.\n\nEligible participants with uncontrolled hypertension despite ongoing antihypertensive therapy will be randomly assigned in a 1:1 ratio to either a CART BP Pro-guided management group or a usual care group based on conventional office blood pressure measurements. Antihypertensive treatment in both groups will follow guideline-based therapy using standard agents including angiotensin receptor blockers, calcium channel blockers, and thiazide diuretics.\n\nThe primary efficacy endpoint is the between-group difference in 24-hour mean systolic blood pressure at 24 weeks measured using ambulatory blood pressure monitoring. Safety will be assessed by the incidence of treatment-emergent adverse events during the study period.",[61],"Hypertension",[61,63,64,65,66],"Ambulatory blood pressure monitoring","Cuffless blood pressure monitoring","Wearable blood pressure device","CART BP Pro","RECRUITING","2026-04-26",{"date":70,"type":37},"2026-04-30",{"date":72,"type":37},"2025-10-22",{"date":74,"type":21},"2027-07-31",{"name":43,"class":44},3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100614529","cgm-based-glycemic-analysis-after-esi-100614529","NCT07280780","CGM-Based Glycemic Analysis After ESI","Continuous Glucose Monitoring-Based Evaluation of Glycemic Fluctuations Following Epidural Steroid Injections: A Comparative Study by Diabetic Status","CGMSteroid","Inclusion Criteria:\n\n* Adults aged 20 to 60 years.\n* Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic.\n* Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device.\n\nExclusion Criteria:\n\n* Patients currently taking or administering steroid medications.\n* Patients with Type 1 Diabetes Mellitus.\n* Patients with Cushing's disease.\n* Patients who have received an epidural steroid injection within the last 3 months.\n* Patients with a known allergy to contrast media.\n* Patients taking anticoagulants or antiplatelet agents.\n* Patients unable to use a Continuous Glucose Monitoring (CGM) device.","20 Years",{"count":87,"type":21},36,"The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.\n\nThe main questions it aims to answer are:\n\nDoes the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?\n\nResearchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.\n\nParticipants will:\n\n* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously\n* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3\n* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection",[90,91,92,93,94],"Type 2 Diabetes (T2DM)","Hyperglycemia","Radicular Pain","Spinal Stenosis","Intervertebral Disc Herniation",[96,97,98,99,100],"epidural steroid injection","Continuous Glucose Monitoring","Dexamethasone","Glycemic Variability","Time in range","2026-04-07",{"date":103,"type":37},"2026-04-09",{"date":105,"type":21},"2026-04-20",{"date":107,"type":21},"2026-12-31",{"name":43,"class":44},1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":56,"phases":121,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":109},"100611866","non-invasive-blood-pressure-monitoring-in-intracranial-aneurysm-embolization-100611866","NCT07246148","NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization","A Randomized Controlled Trial on Non-Invasive Continuous Blood Pressure Monitoring as an Alternative to Radial Arterial Catheterization in Patients Undergoing Coil Embolization for Intracranial Aneurysms","NOVA","Inclusion Criteria:\n\n* Adult patients (≥19 and ≤80 years old) scheduled for elective coil embolization of unruptured intracranial aneurysms under general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status classification I-III.\n\nExclusion Criteria:\n\n* Patients who do not provide informed consent.\n* Patients unable to understand or follow study instructions due to physical or mental limitations.\n* Patients in whom radial arterial catheterization is not feasible (e.g., peripheral vascular disease, skin disorders at the insertion site, absence of radial\u002Fulnar artery, or orthopedic conditions of the upper extremity).\n* Patients with peripheral vascular circulatory disorders.\n* Patients with morbid obesity (BMI ≥ 40 kg\u002Fm²) \\[Eley et al., 2021\\].\n* Patients who are hemodynamically unstable preoperatively or expected to be unstable during the perioperative period.","80 Years",{"count":120,"type":21},50,[58],"The goal of this clinical trial is to evaluate whether non-invasive continuous blood pressure monitoring (NVBP) using the ClearSight system can safely serve as an alternative to radial arterial catheterization for invasive arterial blood pressure monitoring (IABP) in patients undergoing coil embolization for unruptured intracranial aneurysms.\n\nThe main questions it aims to answer are:\n\n* Does NVBP monitoring detect intraoperative hypotension and hypertension events with similar reliability compared to IABP?\n* Does NVBP monitoring reduce the need for invasive arterial catheterization without compromising patient safety or clinical outcomes?\n\nResearchers will compare patients assigned to NVBP monitoring with those receiving conventional IABP monitoring.\n\nParticipants will:\n\n* Be randomly assigned to NVBP monitoring or standard IABP monitoring during coil embolization.\n* Receive continuous monitoring of cerebral oxygenation with near-infrared spectroscopy (rSO₂).\n* Undergo standard anesthesia induction, maintenance, and postoperative intensive care protocols.\n* Have their intraoperative hemodynamic events, vasopressor use, and postoperative outcomes recorded up to 30 days after the procedure.",[124,125,126,127,128],"Cerebral Aneurysms","Intracranial Aneurysms","Coil Embolization","Hemodynamic Instability","Noninvasive Cardiac Monitoring",[130,131,132,133,134,135],"non-invasive blood pressure monitoring","continuous arterial blood pressure monitoring","coil embolization","neuroanesthesia","cerebral oximetry","radial arterial catheterization","2026-04-06",{"date":103,"type":37},{"date":139,"type":37},"2026-01-01",{"date":141,"type":21},"2027-08-31",{"name":43,"class":44},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":56,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100632226","phase-2-fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k-100632226","NCT07510932","Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","FIRST-K","Inclusion Criteria:\n\n* \\[Signed Written Informed Consent\\]\n\nSubjects who voluntarily provide signed written informed consent after receiving sufficient explanation of this clinical trial prior to initiation of any study-related procedures.\n\n\\[Age and Sex\\]\n\nSubjects aged 19 years or older at the time of signing the informed consent.\n\nFor women of childbearing potential, a negative urine β-hCG pregnancy test within 14 days prior to the first administration of the investigational product (IP) is required.\n\nWomen will be considered not of childbearing potential if they meet any of the following criteria; women who do not meet these criteria will be considered of childbearing potential.\n\n1. Women older than 50 years of age who have experienced amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments.\n2. Documented irreversible surgical sterilization, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n\n   (Tubal ligation is not permitted.)\n3. Women 50 years of age or younger who have experienced amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments, and whose luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels fall within the postmenopausal range according to the institutional laboratory standards.\n4. Subjects with hCG-producing tumors may be enrolled at the discretion of the Principal Investigator.\n\n   Subjects must agree to use effective contraception from the first administration of the investigational product until at least 4 weeks after the last administration.\n\n   Female subjects of childbearing potential (or male subjects with female partners of childbearing potential) must use an effective method of contraception during the study treatment period and for at least 4 weeks after the last dose of the investigational product.\n\n   Male subjects who have not undergone vasectomy (or female subjects with male partners) must use effective contraception during the study treatment period and for at least 4 weeks after the last dose, and must not donate sperm during this period.\n\n   ※ Effective contraception methods include: Hormonal contraceptives (subdermal implants, injectable contraceptives, oral contraceptives, etc.), intrauterine devices (IUDs) or intrauterine hormone-releasing systems (IUSs), sterilization of the subject or partner (e.g., vasectomy or bilateral tubal ligation), or sexual abstinence, provided that abstinence is consistent with the subject's usual lifestyle.\n\n   \\[Target Population\\]\n\n   Metastatic colorectal cancer patients intolerant to second-line standard chemotherapy:\n\n   Patients with histologically or cytologically confirmed metastatic or recurrent colorectal cancer who have received two prior systemic treatment regimens (first-line and second-line) including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.\n\n   Recurrence within 6 months after completion of adjuvant therapy will be considered as progression during first-line treatment.\n\n   Subjects with an expected life expectancy of at least 3 months.\n\n   ECOG performance status of 0 or 1.\n\n   Evaluable disease according to RECIST version 1.1. (Measurable disease is not required.)\n\n   Subjects must be able to swallow oral medications.\n\n   \\[Clinical Laboratory Tests\\]\n\n   Bone marrow function\n\n   Hemoglobin (Hb) \\> 9.0 g\u002FdL\n\n   Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL\n\n   Platelet count (PLT) ≥ 75 × 10⁹\u002FL\n\n   Renal function\n\n   Serum creatinine ≤ 1.5 × ULN or creatinine clearance \\> 30 mL\u002Fmin\n\n   Hepatic function\n\n   Total bilirubin ≤ 2.0 × ULN (In cases of biliary obstruction, the criteria must be met after appropriate biliary drainage.)\n\n   AST and ALT ≤ 3 × ULN (≤ 5 × ULN in patients with liver metastases)\n\n   Cardiac function\n\n   QTc ≤ 480 msec\n\n   If QTc exceeds 480 msec, QTc should be measured three consecutive times, and the subject may be enrolled if the average QTc value is \\\u003C 480 msec.\n\n   Exclusion Criteria:\n   * \\[Interventional Treatments\\]\n\n   Subjects who received an investigational product in another clinical trial within 14 days prior to the first administration of the investigational product in this study.\n\n   Subjects who received cytotoxic chemotherapy within 14 days prior to the first administration of the investigational product, or monoclonal antibody therapy within 4 weeks prior to the first administration of the investigational product.\n\n   Subjects who received radiotherapy involving more than 30% of the bone marrow within 4 weeks prior to the first administration of the investigational product, or palliative radiotherapy to a limited field within 2 weeks prior to the first administration.\n\n   Subjects with persistent toxicities ≥ Grade 1 according to CTCAE from prior anticancer therapy that have not resolved before the first administration of the investigational product (except for alopecia).\n\n   \\[Medical History and Concurrent Diseases\\]\n\n   Women who are pregnant or breastfeeding.\n\n   Subjects with active, severe, or uncontrolled infection.\n\n   Subjects with clinically significant cardiovascular disease, including but not limited to:\n\n   Acute coronary syndrome within 6 months\n\n   Congestive heart failure ≥ NYHA (New York Heart Association) Class II\n\n   QTc prolongation or uncontrolled hypertension\n\n   Other significant cardiovascular conditions (e.g., clinically significant arrhythmias or congenital long QT syndrome)\n\n   Subjects with progressive brain metastases, defined as unstable or symptomatic brain lesions.\n\n   Subjects whose lesions have been stable for at least 4 weeks following radiotherapy or surgery may be eligible for enrollment.\n\n   (Leptomeningeal metastasis is excluded.)\n\n   Subjects with active infections such as hepatitis B (HBV), hepatitis C (HCV), or HIV.\n\n   However, enrollment is permitted under the following conditions:\n\n   Subjects who are HBsAg positive may be enrolled if HBV DNA is below the lower limit of quantification according to local laboratory testing.\n\n   Subjects with chronic HBV infection (HBsAg positive and HBV DNA positive) may be enrolled if they have received antiviral therapy for at least 3 months and are considered not to have active hepatitis at the investigator's discretion.\n\n   Subjects with a history of previous HBV infection (IgG anti-HBc positive) may be enrolled if HBV DNA is below the lower limit of quantification.\n\n   Subjects who are anti-HCV antibody positive may be enrolled if HCV RNA is below the lower limit of quantification.\n\n   Subjects who underwent major surgery within 4 weeks prior to the first administration of the investigational product, or who have not adequately recovered from surgery.\n\n   Subjects with a history of thrombosis within 6 months prior to the first administration of the investigational product.\n\n   Subjects with a history or evidence of bleeding disorders.\n\n   Subjects who are receiving high-dose anticoagulant therapy for therapeutic purposes.\n\n   Subjects with non-healing wounds, active ulcers, or bone fractures.\n\n   Subjects with a history of gastrointestinal perforation, active gastrointestinal bleeding, or abdominal fistula within the past 6 months.\n\n   Subjects with proteinuria.\n\n   If the urine dipstick test shows ≥2+ proteinuria, a 24-hour urine protein test or urine protein\u002Fcreatinine ratio (UPCR) should be performed.\n\n   Subjects will be excluded if:\n\n   24-hour urine protein \\> 1 g, or\n\n   UPCR \\> 1.0\n\n   Subjects with a history of surgery affecting drug absorption or with severe gastrointestinal disorders that may interfere with drug absorption.\n\n   Subjects with a history of another primary malignancy, except for:\n\n   Adequately treated non-melanoma skin cancer, or\n\n   Stage I cancer that has shown no recurrence for at least 36 months after curative resection\n\n   Subjects with known hypersensitivity to the active ingredient or excipients of the investigational product, including:\n\n   Hypersensitivity or allergy to Allura Red (relevant to Fruquintinib capsule 5 mg)\n\n   Hypersensitivity or allergy to Tartrazine (FD\\&C Yellow No.5) or Sunset Yellow FCF (FD\\&C Yellow No.6) (relevant to Fruquintinib capsule 1 mg)\n\n   Subjects who are scheduled to undergo major surgery during the study period.\n\n   Subjects who have medical, psychiatric, or cognitive conditions that may interfere with the understanding of study information, performance of study procedures, or provision of written informed consent.\n\n   Subjects who are considered inappropriate for participation in the study at the discretion of the Principal Investigator.",{"count":151,"type":21},88,[153],"PHASE2","Background Patients with metastatic colorectal cancer who have progressed after treatment with oxaliplatin- and irinotecan-based chemotherapy, as well as anti-EGFR monoclonal antibodies (cetuximab or panitumumab) according to RAS mutation status, or anti-angiogenic agents (bevacizumab, ramucirumab, or aflibercept), have limited therapeutic options in the third-line setting. The phase III SUNLIGHT trial evaluating TAS-102 (trifluridine\u002Ftipiracil) in combination with bevacizumab demonstrated promising outcomes, with a median progression-free survival (PFS) of 5.6 months and a median overall survival (OS) of 10.8 months. However, approximately 30% of patients in that study had not previously received bevacizumab during first- or second-line treatment, indicating that a proportion of patients had not been fully exposed to current standard therapies for metastatic colorectal cancer. Therefore, there remains an unmet need to evaluate additional therapeutic strategies in patients who have received optimal prior standard treatments. This study aims to evaluate the efficacy and safety of fruquintinib as a third-line treatment in this population.\n\nHypothesis Proactive and comprehensive supportive care will not only help manage fruquintinib-related toxicities (e.g., hypertension, hand-foot syndrome, proteinuria, and fatigue), but also enable patients to maintain treatment, thereby potentially prolonging progression-free survival (PFS).\n\nStudy Design This is a multicenter, single-arm, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of fruquintinib in combination with supportive care in patients with metastatic colorectal cancer who are intolerant to second-line standard chemotherapy. All subjects will receive fruquintinib treatment in combination with supportive care. Supportive care refers to medical interventions aimed at preventing and managing adverse events associated with fruquintinib, including but not limited to hypertension, proteinuria, diarrhea, fatigue, and hand-foot syndrome.",[156],"Colon Cancer","2026-03-31",{"date":136,"type":37},{"date":160,"type":21},"2026-05-01",{"date":162,"type":21},"2027-09-01",{"name":43,"class":44},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":56,"phases":175,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":194,"locationsCount":109},"100608461","peri-habilitation-for-patients-with-gastric-cancer-100608461","NCT07201857","Peri-habilitation for Patients With Gastric Cancer","Peri-habilitation to Enhance Treatment Outcomes and Postoperative Recovery in Patients With Gastric Cancer","Inclusion Criteria:\n\n* Patients aged 65 years or older who have been diagnosed with gastric cancer and are scheduled to undergo surgical treatment or chemotherapy.\n\nExclusion Criteria:\n\n* Patients with severe conditions who are unable to undergo the intervention prior to surgical treatment or chemotherapy.\n* Patients with physical (e.g., musculoskeletal) or mental disorders that make participation in or continuation of the program impossible.\n* Patients judged to be at risk of additional physical burden from the intervention.","65 Years","90 Years",{"count":174,"type":21},30,[58],"This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and nutrition intervention for about three weeks after hospital discharge, and by analyzing its effects on the prevention of postoperative complications and recovery.",[178,179,180,181,182],"Gastric Cancer (Diagnosis)","Gastric Cancer Patient","Gastric Cancer Patients Undergoing Gastrectomy","Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy","Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy",[184,185,186,187],"peri-habilitation","gastric cancer","postoperative recovery","exercise intervention","2025-09-23",{"date":190,"type":37},"2025-10-01",{"date":192,"type":21},"2025-10-15",{"date":107,"type":21},{"name":43,"class":44},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":202,"sex":17,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":56,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100575841","skin-to-skin-contact-in-healthy-term-infants-100575841","NCT06777524","Skin-to-skin Contact in Healthy Term Infants","Short-term and Long-term Effects of Skin-to-skin Contact in Healthy Term Infants","Inclusion Criteria:\n\n* Babies born at Korea University Anam Hospital\n* Term infants (37 weeks or more)\n* Infants with a birth weight of 2,500g or more\n* Healthy infants with an Apgar score of 7 or higher at 5 minutes\n* Mothers and infants without severe acute complications, such as requiring intensive care treatment immediately after delivery\n\nExclusion Criteria:\n\n* Preterm infants born at 37 weeks of less gestation\n* Low birth weight infants weighing less than 2500g at birth\n* Mothers under the age of 20\n* Unmarried mothers\n* Multiple pregnancies (twins or triplets)\n* Parents do not consent to participation in the study",true,"1 Hour","72 Hours",{"count":206,"type":21},130,[58],"This is a prospective, double-blind, randomized controlled clinical trial study to investigate short- and long-term effects of mother-infant skin-to-skin contact in healthy term infants, in order to provide supporting data for emphasizing mother-infant skin contact and family-centered care in South Korea.",[210],"Skin-to-skin Contact",[212,213,214],"skin-to-skin contact","infant","neurodevelopmental outcome","2025-09-18",{"date":188,"type":37},{"date":218,"type":37},"2025-02-10",{"date":220,"type":21},"2030-01-31",{"name":43,"class":44},2,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":56,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":109},"100607472","patient-centered-rehabilitation-program-to-advance-recovery-100607472","NCT07189000","Patient-centered REhabilitation Program to Advance REcovery","A Patient-centered Prehabilitation Program to Enhance Postoperative Recovery in Patients With Malignant Cancer","PREPARE-CAN","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Elective cancer surgery planned under general anesthesia at a participating site (e.g., gastrointestinal, hepatobiliary-pancreatic, thoracic, gynecologic, or other site-approved cancer operations).\n* Ambulatory: able to walk independently (assistive device such as a cane is allowed) and deemed safe to perform a six-minute walk test (6MWT) per investigator judgment.\n* Smartphone access and app use: owns\u002Fhas regular access to a smartphone capable of running the study app and agrees to use the app (notifications, weekly home 6MWT logging, brief daily check-ins).\n* Preoperative lead-in: expected interval of ≈14 days or more between consent\u002Frandomization and surgery to allow prehabilitation exposure (shorter intervals may be screened but must allow minimum onboarding and at least one home 6MWT).\n* Able to understand study procedures and provide written informed consent (Korean or English literacy sufficient to follow app instructions).\n\nExclusion Criteria:\n\n* Emergency surgery or surgery date that cannot accommodate even minimal prehabilitation onboarding.\n* ASA IV or higher, or any unstable\u002Fcritical condition that, in the investigator's opinion, makes participation unsafe.\n* Contraindications to 6MWT\u002Flight walking, including but not limited to: unstable angina, recent myocardial infarction (≤30 days), decompensated heart failure, uncontrolled clinically significant arrhythmia, severe symptomatic aortic stenosis, severe uncontrolled pulmonary disease, or investigator-judged safety concerns (e.g., resting severe hypoxemia, high fall risk).\n* Non-ambulatory status or musculoskeletal\u002Fneurologic conditions that preclude performing a 6MWT.\n* Cognitive impairment or psychiatric\u002Fbehavioral conditions that preclude informed consent or reliable app use.\n* Inability or unwillingness to install\u002Fuse the study app (or lack of regular smartphone access).\n* Concurrent enrollment in another interventional clinical trial that would confound outcomes or burden participants (per investigator judgment).\n* Any other medical or logistical condition that, in the opinion of the investigator, would interfere with protocol adherence, outcome assessment on the preoperative day, or the routine postoperative follow-up visit.",{"count":232,"type":21},60,[58],"The goal of this clinical trial is to learn whether an app-based, patient-centered prehabilitation program improves preoperative functional capacity in adults scheduled for elective cancer surgery. The main questions it aims to answer are:\n\nDoes the program increase the six-minute walk distance (6MWD) measured on the preoperative day (within 24-48 hours before surgery)?\n\nCompared with usual care, does the program improve preoperative adherence to home 6MWT practice and patient-reported anxiety\u002Fdepression (HADS)?\n\nResearchers will compare an app-based prehabilitation program to usual care to see if the program improves preoperative functional capacity.\n\nParticipants will:\n\nUse a study app to perform weekly home six-minute walk tests (6MWT) and complete brief daily check-ins (exercise, nutrition, psychological status) before surgery.\n\nAttend routine preoperative admission (no extra visit) for in-hospital 6MWT (primary endpoint) and brief assessments (grip strength, Timed Up \\& Go, HADS, skeletal muscle mass by InBody where available\u002Ffee-free).\n\nAttend one routine postoperative outpatient visit at 3 or 6 months (site-standard timing) for follow-up assessments.\n\nNo additional study-specific clinic visits are required outside usual care.",[236,237,238],"Cancer","Frailty","Prehabilitation",[240,241,242],"prehabilitation","frailty","cancer","2025-09-16",{"date":188,"type":37},{"date":139,"type":21},{"date":247,"type":21},"2027-12-31",{"name":43,"class":44},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":256,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":56,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":109},"100575058","phase-4-comparison-of-moderate-intensity-statin-plus-ezetimibe-vs-high-intensity-statin-for-coronary-plaque-stabilization-100575058","NCT06767345","Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE Stabilization","Inclusion Criteria:\n\n* Adult men and women over the age of 18 years.\n* Patients with coronary artery disease undergoing a coronary intervention procedure using intravascular imaging.\n* At least one major native coronary artery (\"target vessel\") meeting all the following criteria for intracoronary imaging immediately following a qualifying PCI procedure:\n\n  * Angiographic evidence of coronary artery stenosis ≥30% by angiographic visual estimation.\n  * Target vessel is accessible to the imaging catheter and suitable for intracoronary imaging in the proximal 50 mm segment.\n  * Target vessel is not a bypass graft (aortic or arterial) or a bypassed graft vessel.\n  * Target vessel has not undergone PCI within the target segment.\n  * Target vessel is not a candidate for PCI at the time of the procedure or for 6 months thereafter (per investigator's judgment).\n* Patients who have provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Left main stem lesion: Left main coronary artery stenosis ≥50% by coronary angiographic visual estimation.\n* History of coronary artery bypass graft surgery (CABG).\n* Unstable clinical condition (hemodynamic or electrical instability).\n* Severe coronary artery calcification or tortuosity interfering with IVUS, NIRS, or evaluation.\n* Uncontrolled cardiac arrhythmia (recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response) not controlled by medication within 3 months prior to screening.\n* Active liver disease or liver dysfunction.\n* Severe renal dysfunction (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Known allergy to contrast media, heparin, aspirin, ticagrelor, or prasugrel.\n* Active infection or major hematologic, metabolic, or endocrine dysfunction as determined by the investigator.\n* Planned surgery within 12 months.\n* Currently enrolled in another investigational device or drug study.\n* Estimated life expectancy of less than 2 years.\n* Women of childbearing potential (under 50 years of age) who:\n\n  * Had their last menstrual period within the last 12 months.\n  * Have not had tubal ligation, oophorectomy, or hysterectomy.","18 Years",{"count":258,"type":21},408,[260],"PHASE4","This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is non-inferior to monotherapy in stabilizing coronary plaques over 52 weeks. The primary endpoint is the percentage change in coronary atheroma volume (PAV) assessed by grayscale IVUS, with secondary outcomes including changes in lipid core burden, inflammatory markers, and clinical events like myocardial infarction and ischemic stroke. The study plans to enroll 408 patients undergoing coronary intervention across 7 domestic institutions, with rigorous follow-up protocols and adherence to international research guidelines.",[263,264,265],"Coronary Artery Disease","Atherosclerosis of Coronary Artery","Plaque, Atherosclerotic","2025-09-08",{"date":268,"type":37},"2025-09-15",{"date":270,"type":37},"2025-05-12",{"date":272,"type":21},"2028-06-25",{"name":43,"class":44},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":281,"targetDuration":4,"studyType":56,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":109},"100552510","a-clinical-trial-to-evaluate-the-safety-and-efficacy-of-neuromodulation-using-exablate-4000-type-21-in-patients-with-psychostimulant-use-disorderpud-100552510","NCT06474026","A Clinical Trial to Evaluate the Safety and Efficacy of Neuromodulation Using 'ExAblate 4000 Type 2.1' in Patients With Psychostimulant Use Disorder(PUD)","Safety and Efficacy of Neuromodulation Using 'ExAblate 4000 Type 2.1' in Patients With Psychostimulant Use Disorder(PUD): a Single-center, Evaluators-blind, Prospective, Randomized, Feasibility, Investigator-initiated Trial","Inclusion Criteria:\n\n1. Adults between the ages of 19 and 60\n2. Subject is diagnosed with a DSM-5 psychostimulant\\* use disorder (PUD) by a board certified psychiatrist.\n\n   \\*Psychostimulants: Methamphetamine, cocaine, and other stimulants\n3. Subject is currently receiving standard substance use disorder inpatient treatment or an intensive outpatient program\n4. Subject has been off psychostimulants and other illicit drugs, confirmed via urine toxicology screen\n5. Subject has not regularly used illegal drugs other than psychostimulants more than once a month in the past six months\n6. The NAc is apparent on MRI such that treatment targeting can be performed directly (visible on MRI) and indirectly (using other anatomical structures for measurements)\n7. Subject is able to communicate sensations during the investigational procedure\n8. Subject has made a voluntary decision to participate in this clinical trial and has given written consent.\n9. Subject is willing to comply to the protocol\n\nExclusion Criteria:\n\n1. Subject with standard contraindication for MR imaging, such as non-MRI compatible implanted metallic devices.\n2. Subject with known allergies to the MRI contrast agent gadolinium (Gadovist®) or contraindication (such as untreated hypokalemia).\n3. Subject who are unable or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours)\n4. More than 30% of the skull area traversed by the sonication pathyway is covered by scars, scalp disorder (e.g., eczema), or atrophy of the scalp.\n5. Subject with implanted objects in the skull or brain\n6. Subject diagnosed with advanced kidney disease or on dialysis\n7. Subjet with impaired renal function with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1.73 m 2\n8. Subject with known unstable cardiac status or severe hypertension including:\n\n   * Documented myocardial infarction within six months of enrollment\n   * Unstable angina on medication\n   * Unstable or worsening congestive heart failure\n   * Left ventricular ejection fraction (LVEF) below the lower limit of normal\n   * History of hemodynamically unstable cardiac arrhythmias\n   * Cardiac pacemaker\n   * Severe hypertension (diastolic blood pressure over 100 on medication)\n9. Subject has a history of abnormal bleeding or coagulopathy\n10. Subject is receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk of hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure\n11. Subject has blood coagulation test results outside the normal range\n\n    * PLT\\\u003C100,000\u002FμL\n    * PT\\>13.9 seconds or PTT\\>37.5 seconds\n    * INR\\>1.2\n12. Subject with cerebrovascular disease as determined by MRI according to Fazekas score\n13. Subject with a past or current diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or untreated depression other than one determined to be substance induced\n14. Score of greater than 17 on the Hamilton Depression Rating Scale (HAM-D) or increased risk of suicide based on any positive response regarding passive or active suicidal ideation with or without intent over the past 3 months or lifetime history of active suicidal ideation with intent on the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline\n15. Diagnosis of dementia or any other disorder which has led to a clinically significant cognitive impairment (assessed via NIHTB-CB)\n16. Subject with brain tumors\n17. Subject with chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other casues of reduced pulmonary vascular cross-sectional area.\n18. Any known CNS infection or infection with the human immunodeficiency virus (HIV)\n19. Subject who has had deep brain stimulation or a prior stereostatic ablation of the NAc, basal ganglia, or thalamus\n20. Subject who has been administered botulinum toxins into to the arm, neck, or face for 5 months prior to baseline\n21. Subject unwilling to refrain from using illicit drugs while participating in this clinical trial\n22. Subject is pregnant or nursing women\n23. For women of childbearing potential\\*, who do not agree to use clinically appropriate contraception\\*\\* for the duration of the clinical trial\n\n    \\*Definition of women of childbearing age: means women who have experienced menarche, have not been surgically sterilized (hysterectomy or bilateral oophorectomy), or are not post-menopausal, defined as amenorrhea for 12 months or more for no other reason.\n\n    \\*\\*Clinically appropriate contraception: defined as \"\\[intrauterine device (e.g., Loop, Mirena), chemical barrier method (spermicide), or subdermal implantable contraceptive device (e.g., Implanon)\\] + physical barrier method (male or female)\" for women, tubal surgery, or laparoscopic contraception (a type of tubal ligation).\n24. Other, if the investigator determines that participation in the clinical trial is inappropriate ethically or because it may affect the outcome of the clinical trial",{"count":282,"type":21},10,[58],"The purpose of this clinical trial is to evaluate the initial safety and efficacy of the ExAblate Model 4000 Type 2.1 surgical device for nucleus accumbens (NAc) neuromodulation in patients with psychostimulant use disorder (PUD).",[286],"Psychostimulant Use Disorder(PUD)",[288,289,290],"ExAblate 4000 Type 2.1","Psychostimulant use disorder","neuromodulation","2025-08-28",{"date":293,"type":37},"2025-09-05",{"date":295,"type":37},"2024-07-01",{"date":297,"type":21},"2026-07-31",{"name":43,"class":44},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":56,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":109},"100576195","phase-4-effects-of-enavogliflozin-on-coronary-microvascular-and-cardiac-function-in-obesity-100576195","NCT06782139","Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity","Effects of ENavogliflozin on Coronary microVascular and Cardiac Function in Patients With obesitY (ENVY)","ENVY","Inclusion Criteria: The following criteria must be met for inclusion in the study:\n\n1. Obesity or Abdominal Obesity:\n\n   Body Mass Index (BMI) ≥ 25 kg\u002Fm², or Waist circumference: Male ≥ 90 cm, Female ≥ 85 cm.\n2. Diabetes:\n\nHemoglobin A1c ≥ 6.5%, or Fasting blood glucose ≥ 126 mg\u002FdL after 8 hours of fasting, or Currently on antidiabetic medication. Blood test results must be within 3 months prior to enrollment.\n\nOther inclusion criteria:\n\nAge between 20 and 79 years. Patients who have undergone coronary flow velocity reserve testing. For baseline echocardiography, left ventricular diastolic dysfunction will be evaluated structurally (LV dimension, LV mass index, LA size) and hemodynamically (Doppler data, left ventricular ejection fraction, strain data).\n\nExclusion Criteria:\n\n1. Left ventricular ejection fraction (LVEF) \\\u003C 50%\n2. History of coronary artery disease, or patients who have undergone coronary artery intervention or coronary artery bypass grafting.\n3. Patients with suspected obstructive coronary artery disease, including those with chest pain and positive stress test results (e.g., exercise treadmill test, dobutamine stress echocardiography, myocardial perfusion imaging).\n4. Second-degree or higher atrioventricular block, symptomatic bradycardia, sick sinus syndrome, or Wolff-Parkinson-White syndrome.\n5. Chronic kidney disease (GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or end-stage renal disease on hemodialysis or peritoneal dialysis.\n6. Asthma, chronic obstructive pulmonary disease, or primary pulmonary hypertension.\n7. Moderate or severe valvular heart disease or congenital heart disease, or patients with a history of open-heart surgery.\n8. Active cancer within the last 5 years, or patients currently receiving chemotherapy.\n9. Vasculitis associated with autoimmune diseases, such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).\n10. Patients who cannot undergo exercise testing, such as treadmill or bicycle ergometer testing.\n11. Use of any other SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) within the past 6 months, or a known allergy to these drugs.\n12. Pregnant or breastfeeding women.\n13. Women planning pregnancy during the study period (or within 24 weeks from the start of the study, including the 12-week observation period).\n14. Acute urinary tract infection at the time of enrollment.","79 Years",{"count":174,"type":21},[260],"The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.",[312],"Obesity and Type 2 Diabetes",[314,315,316,317,318],"Sodium-Glucose Cotransporter 2 inhibitors","Obesity","Diabetes","Coronary microvascular function","Epicardial adipose tissue","2025-08-25",{"date":321,"type":37},"2025-09-02",{"date":323,"type":37},"2025-01-20",{"date":325,"type":21},"2025-12-31",{"name":43,"class":44},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":118,"enrollmentInfo":334,"targetDuration":4,"studyType":56,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":109},"100425643","exercise-capacity-according-to-coronary-microvascular-dysfunction-and-body-composition-100425643","NCT04822649","Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition","Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients With Suspected Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n* Age 20 to 80\n* Typical\u002Fatypical chest pain or ischemic symptoms including dyspnea\n* No significant coronary artery stenosis (\\>50% stenosis) in coronary angiography or computed tomography\n* Left ventricular ejection fraction ≥50%\n\nExclusion Criteria:\n\n* More than moderate valvular heart disease\n* Congenital heart disease\n* Chronic renal failure (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis\n* Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension\n* Receiving anticancer drugs\n* Vasculitis associated with autoimmune diseases\n* Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer)\n* Atrial fibrillation\n* Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients",{"count":335,"type":21},100,[58],"The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.",[339],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[341],"body composition, CPET, CFR, coronary microvascular dysfunction (CMD), frailty, HFpEF",{"date":321,"type":37},{"date":344,"type":37},"2021-04-15",{"date":325,"type":21},{"name":43,"class":44},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":56,"phases":354,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":109},"100602392","phase-1-the-effect-of-repetitive-transcranial-magnetic-stimulation-on-cognitive-improvement-in-dementia-with-lewy-bodies-100602392","NCT07122908","The Effect of Repetitive Transcranial Magnetic Stimulation on Cognitive Improvement in Dementia With Lewy Bodies","Inclusion Criteria:\n\n* Over 65 years of age\n* Meeting the criteria for Probable DLB as proposed in the 2017 DLB diagnostic criteria\n* Scoring between 0.5 and 1 on the Clinical Dementia Rating Scale (CDR)\n\nExclusion Criteria:\n\n* If other causes of cognitive impairment are suspected, such as neurosyphilis, hypothyroidism, hyperthyroidism, metabolic encephalopathy, brain tumor, acute cerebral hemorrhage, acute cerebral infarction, previous territorial or strategic cerebral infarction, Wernicke's encephalopathy, or severe white matter hyperintensity detected in hematological tests, brain MRI, etc.\n* If cooperation for interviews and self-assessment is difficult (e.g., due to hearing impairment, language disorders, severe psychotic conditions)\n* If there is a history of psychiatric disorders: major affective disorder, schizophrenia, or schizo-affective disorder\n* If electroencephalography (EEG) cannot be performed\n* If epileptiform EEG findings are present or if the patient is currently receiving antiepileptic drugs.",{"count":282,"type":21},[355,153],"PHASE1","This study aimed to investigate the feasibility of repetitive transcranial magnetic stimulation (rTMS) on the occipital lobe in patients with Lewy body dementia.\n\nThis is a proof-of-concept study to evaluate the safety and effect of occipital lobe stimulation in patients with Lewy body dementia. Over a period of two weeks, participants will receive rTMS to the primary visual cortex three times a week during visits. For the remaining 10 weeks, maintenance therapy will be administered with rTMS once a week during visits. Efficacy assessments will be conducted on the day of the final stimulation session and again four weeks later.",[358],"Dementia With Lewy Bodies","2025-08-07",{"date":361,"type":37},"2025-08-14",{"date":363,"type":37},"2024-04-11",{"date":365,"type":21},"2026-12",{"name":43,"class":44},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":373,"enrollmentInfo":374,"targetDuration":376,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":222},"100576495","clinical-impact-of-non-invasive-neurally-adjusted-ventilatory-assist-in-very-preterm-infants-100576495","NCT06786039","Clinical Impact of Non-invasive Neurally Adjusted Ventilatory Assist in Very Preterm Infants","Inclusion Criteria:\n\n* Preterm infants born between 27 weeks 0 days to 31 weeks 6 days of gestation\n* Preterm infants who require respiratory support within the first 48 hours of life\n\nExclusion Criteria:\n\n* Preterm infants who die within the first 48 hours of life\n* Preterm infants who do not require any respiratory support within the first 48 hours of life.\n* Preterm infants with congenital anomalies affecting the lungs, heart, or other organs that could influence breathing\n* Infants whose parents do not consent to participate in the study","48 Hours",{"count":375,"type":21},80,"2 Years","This is a prospective observational study investigating the impact of NIV-NAVA on short-term clinical outcomes and long-term neurodevelopment in very preterm infants.",[379],"Preterm Infant",[381,382],"infant, premature","Noninvasive NAVA","2025-06-12",{"date":385,"type":37},"2025-06-17",{"date":323,"type":37},{"date":388,"type":21},"2030-12-20",{"name":43,"class":44},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":17,"minAge":256,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":56,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":109},"100575091","phase-4-comparison-of-pitavastatin-plus-ezetimibe-versus-high-intensity-statin-therapy-on-risk-of-new-onset-diabetes-mellitus-100575091","NCT06767774","Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease","Inclusion Criteria:\n\n* Age Requirement:\n\n  * Patients aged 18 years or older.\n\nGlycemic Status:\n\n* Patients who are not taking oral hypoglycemic agents (OHAs) and meet all of the following criteria:\n\n  * Fasting glucose less than 126 mg\u002FdL.\\*\n  * HbA1c less than 6.5%.\n  * Plasma glucose less than 200 mg\u002FdL after 2 hours during a 75 g oral glucose tolerance test (OGTT).\\*Note: For fasting glucose, two measurements of 126 mg\u002FdL or greater within 3 months are required for a diagnosis of diabetes.\n\nCardiovascular Disease:\n\n* Patients with established atherosclerotic cardiovascular disease, defined as having at least one of the following:\n\n  * Coronary Heart Disease (CHD):\n\n    * Documented history of myocardial infarction (MI).\n    * History of coronary revascularization.\n\n      * 50% stenosis of a major epicardial coronary artery confirmed by cardiac catheterization, computed tomography (CT), or coronary angiography.\n  * Cerebrovascular Disease:\n\n    \\>History of stroke of atherosclerotic origin.\n    * History of carotid revascularization.\n\n      \\>≥50% stenosis of the carotid artery confirmed by X-ray angiography, magnetic resonance (MR) angiography, CT angiography, or Doppler ultrasound.\n  * Symptomatic Peripheral Arterial Disease (PAD):\n\n    \\>Intermittent claudication with an ankle-brachial index (ABI) of 0.90 at rest.\n    * Intermittent claudication with ≥50% stenosis of a peripheral artery (excluding the carotid artery) confirmed by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound.\n    * History of revascularization of peripheral arteries (excluding carotid arteries).\n    * Lower extremity amputation at or above the ankle due to atherosclerotic disease (excluding trauma or osteomyelitis).\n\nDietary Requirements:\n\n* Patients must be on a stable diet prior to randomization and able to adhere to the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Change (TLC) diet or an equivalent throughout the study.\n\nInformed Consent:\n\n* Subjects or their legal representatives must provide written informed consent to the study protocol and clinical follow-up schedule.\n* An informed consent form approved by the institutional review board (IRB)\u002Fethics committee of the study site must be signed.\n\nExclusion Criteria:\n\n* Patient is pregnant or breastfeeding or of childbearing potential.\n* Requires concomitant administration of strong inhibitors of CYP3A4 (itraconazole, ketoconazole, protease inhibitors, erythromycin, clarithromycin, telithromycin, and nefazodone) or CYP2C9 (relative contraindication not dependent on CYP450 statins).\n* Chronic kidney disease (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m²) or dialysis-dependent renal failure.\n* Uncontrolled hypothyroidism.\n* Personal or family history of an inherited muscle disorder.\n* History of statin-induced muscle toxicity.\n* Alcohol-dependent person.\n* Hypersensitivity to statins and ezetimibe.\n* Hemodynamic instability at the time of enrollment: cardiogenic shock, refractory ventricular arrhythmia, or congestive heart failure (New York Heart Association class IV) at randomization.\n* History of hemorrhagic stroke or intracranial hemorrhage, TIA, or ischemic stroke within the past 6 months.\n* Planned surgery requiring discontinuation of statins or ezetimibe within 6 months of randomization.\n* Current treatment for active cancer.\n* Clinically significant abnormal findings identified at the screening visit, physical examination, laboratory tests, or electrocardiogram that, in the investigator's judgment, may interfere with safe completion of the study.\n* Liver disease or biliary obstruction, elevated liver enzymes (ALT or AST \\> the upper limit of normal) or elevated total bilirubin (total bilirubin \\> 2 times the upper limit of normal) at screening.\n* Life expectancy for noncardiac or cardiac causes \\\u003C 1 year.\n* Unwillingness or inability to comply with the procedures described in this protocol.\n* Previously diagnosed with diabetes mellitus and compliant with lifestyle modification and taking oral hypoglycemic agents (OHAs) or insulin.",{"count":398,"type":21},2000,[260],"The AVOID-DM trial is a multicenter, prospective, randomized study comparing the risk of new-onset diabetes mellitus (DM) between two cholesterol-lowering strategies in patients with prediabetes and established atherosclerotic cardiovascular disease (ASCVD). The study evaluates pitavastatin plus ezetimibe combination therapy versus high-intensity statin monotherapy (rosuvastatin 20 mg). Enrolling 2,000 non-diabetic participants with ASCVD, subjects are randomized 1:1 into the two treatment arms. The primary outcome is the incidence of new-onset DM over a follow-up period of up to 36 months. Secondary outcomes include cardiovascular events, changes in LDL cholesterol, fasting glucose, HbA1c, and insulin resistance. This trial hypothesizes that the combination therapy will achieve LDL targets with a lower risk of new-onset DM compared to high-intensity statin monotherapy.",[402,316,403],"ASCVD","Statin","2025-04-24",{"date":406,"type":37},"2025-04-27",{"date":408,"type":37},"2025-04-25",{"date":220,"type":21},{"name":43,"class":44},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":118,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":109},"100521973","sex-difference-of-coronary-microvascular-dysfunction-in-patients-with-non-obstructive-coronary-artery-disease-100521973","NCT06076551","Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease","Sex Difference of Coronary Microvascular Dysfunction Evaluated by Coronary Flow Reserve in Patients With Non-obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* Typical\u002Fatypical chest pain or ischemic symptoms including dyspnea\n* No significant coronary artery stenosis (\\\u003C50% stenosis) in coronary angiography or computed tomography\n\nExclusion Criteria:\n\n* ≥ Moderate valvular heart disease\n* Congenital heart disease\n* Chronic renal failure (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis\n* Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension\n* Receiving anticancer drugs\n* Vasculitis associated with autoimmune diseases\n* Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients",{"count":419,"type":21},300,"Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease",[422],"Microvascular Angina","2025-03-24",{"date":425,"type":37},"2025-03-26",{"date":427,"type":37},"2018-02-01",{"date":325,"type":21},{"name":43,"class":44},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":109},"100578924","arthroscopic-rotator-cuff-repair-with-uc-mscs-for-large-to-massive-tears-100578924","NCT06817616","Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears","Arthroscopic Rotator Cuff Repair with Umbilical Cord-derived Mesenchymal Stem Cells for Large to Massive Rotator Cuff Tears","Inclusion Criteria:\n\n* Male or female 19 years of age and older\n* Unilateral shoulder pain with a pain score of 4 or higher.\n* patients with a symptom duration of at least three months who have not responded to conventional treatments, including analgesics.\n* patients diagnosed with massive or extensive full-thickness rotator cuff tears confirmed by computed tomography arthrography or magnetic resonance imaging.\n\nExclusion Criteria:\n\n* patients diagnosed with small or medium full-thickness rotator cuff tears among study participants with full-thickness rotator cuff tears.\n* patients who have received subacromial injection therapy in the affected shoulder within the past three months.\n* patients who have undergone rotator cuff surgery on the affected shoulder within the past six months.\n* patients exhibiting or suspected of having the following radiological findings: malignant tumors, severe glenohumeral osteoarthritis, or bony abnormalities causing subacromial space narrowing.\n* patients presenting with symptomatic cervical spine disorders.\n* patients experiencing bilateral shoulder pain.\n* patients diagnosed with multiple arthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.\n* patients with neurological deficits.\n* Pregnant or breastfeeding patients\n* patients unwilling to use effective contraception during the study period.\n* patients currently infected with HBV, HCV, or HIV, or those with a positive RPR test result.\n* patients with severe conditions that may affect the study, including cardiovascular diseases, renal diseases, hepatic diseases, endocrine disorders, or malignancies.\n* patients who are unable to comprehend the questionnaires used for study assessments, including the Visual Analog Scale (VAS), or those with communication difficulties due to psychiatric disorders.\n* Any other cases deemed inappropriate for study participation by the investigator.",{"count":438,"type":21},15,[58],"Safety Analysis of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients Undergoing Rotator Cuff Repair for Massive or Large Rotator Cuff Tears",[442],"Rotator Cuff Disease","2025-02-17",{"date":445,"type":37},"2025-02-18",{"date":447,"type":37},"2025-01-17",{"date":449,"type":21},"2026-04",{"name":43,"class":44},{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":56,"phases":460,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":476,"locationsCount":109},"100472123","phase-4-a-study-to-evaluate-the-impact-of-pre-procedural-intracoronary-nicorandil-injection-to-prevent-reduction-of-decreased-timi-flow-in-patients-who-undergoing-percutaneous-coronary-intervention-for-the-coronary-artery-disease-100472123","NCT05427786","A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease","A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease","Inclusion Criteria:\n\n1. Over 19 years old\n2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information\n3. Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease\n\nExclusion Criteria:\n\n1. Patients with TIMI ≤ 2 before coronary intervention\n2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)\n3. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study\n4. Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration\n5. Those whose surviving life is expected to be less than 1 year\n6. Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment",{"count":459,"type":21},460,[260],"The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.",[463,263,464],"No-Reflow Phenomenon","Percutaneous Coronary Intervention",[466,467,468,469],"Nicorandil","No-reflow phenomenon","lipid core burden index","near-infrared spectroscopy","2024-10-08",{"date":472,"type":37},"2024-10-10",{"date":474,"type":37},"2022-12-14",{"date":365,"type":21},{"name":43,"class":44},{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":56,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":109},"100538636","to-assess-with-ezefeno-tab-in-patients-with-dyslipidemia-and-t2dm-100538636","NCT06293417","To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of Non-HDL-C Levels Even With Moderate-intensity Monotherapy","ENSEMBLE","Inclusion Criteria:\n\n* Patients with type 2 diabetes diagnosed by American Diabetes Association criteria\n* Age ≥ 19 years\n* Non-HDL-C ≥100 mg\u002FdL, TG ≥200, \\\u003C500 mg\u002FdL on moderate-intensity statins\n* with cardiovascular risk factor\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.)\n* Patient with myopathy and rhabdomyolysis\n* AST\u002FALT more than 3 ULN\n* Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and\u002For glucose-galactose malabsorption",{"count":486,"type":21},3958,[58],"The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:\n\n* major adverse cardiovascular events within 48 months of the trial duration\n* microvascular events within 48 months of the trial duration",[490,491],"T2DM (Type 2 Diabetes Mellitus)","Dyslipidemias","2024-08-25",{"date":494,"type":37},"2024-08-27",{"date":496,"type":37},"2024-03-01",{"date":498,"type":21},"2027-02-01",{"name":43,"class":44},{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":17,"minAge":507,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":56,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":4},"100552509","a-clinical-trial-to-evaluate-the-initial-safety-and-efficacy-of-repetitive-bbb-blood-brain-barrier-disruption-using-high-intensity-focused-ultrasound-exablate-4000-type-21-in-patients-with-alzheimers-disease-100552509","NCT06474013","A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease","Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease: Single-center, Open, Prospective, Single-arm, Feasibility, Investigator-initiated Trial)","Inclusion Criteria:\n\n1. Age between 50 and 85 years\n2. Total score of 23 or less on the K-MMSE (Korean version of the mini mental state exam)\n3. Positive 18F-Florbetaben (FBB) PET scan\n4. Have mild cognitive impairment or dementia due to Alzheimer's disease, each of which must meet the criteria below.\n\n   * if mild cognitive impairment: amnestic mild cognitive impairment according to Peterson\n   * If dementia: probable Alzheimer's disease dementia, according to the national institute of aging and Alzheimer's association (NIA-AA).\n5. If a subject is taking medication for Alzheimer's disease such as an acetyl-cholinesterase-inhibitor (AChEI) and\u002For memantine, etc., the subject should maintained the stable dosage for at least 3 months.\n6. A subject who is able to express regarding sensation during the application of an investigational medical device in a clinical trial\n7. A subject who has voluntarily decided to participate in this clinical trial and has given written informed consent\n8. A subject who is willing to adhere to the protocol\n\nExclusion Criteria:\n\n1. A severity score of 2 or more for any of the following items on the caregiver-administered neuropsychiatry inventory (CGA-NPI): \"delusions,\" \"hallucinations,\" or \"agitation\u002Faggression.\"\n2. Known sensitivity\u002Fallergy to or contraindication\\* to the MRI contrast agent gadolinium (Gadovist® ) or ultrasound contrast agent Definity®\n3. Have a standard contraindication to MR imaging, such as implanted metal devices that are incompatible with MRI.\n4. Sensitivity\u002Fallergy to or contraindication to local anesthetics and any anesthetic used when conscious sedation is required during application of an investigational medical device in a clinical trial\n5. Anyone who has MRI result as any of the following\n\n   * Severe ischemic changes\\* have been identified.\n\n     \\*Significant ischemic changes: defined as a fazekas score of 3 or greater than 5 lacunes or greater than 3 cerebral microbleeds\n   * active or chronic infection\u002Finflammation\n   * Acute or chronic bleeding\n   * Tumor\u002Fspace-occupying lesion\n   * meningeal enhancement\n   * intracranial hypotension\n6. ≥30% of the skull area traversed by sonication is covered by scars, scalp disorder, or atrophic scalp.\n7. Have a history of seizure disorder or epilepsy that may be worsened by opening the blood-brain barrier\n8. Have a history of bleeding disorders or clotting disorders\n9. Have a serious heart condition or unstable blood flow (e.g., uncontrolled high blood pressure, arrhythmia, angina, etc.)\n10. Decreased renal function (glomerular filtration rate\\\u003C30 mL\u002Fmin\u002F1.73 m )2\n11. Unable to target due to severe brain atrophy\n12. Patient who positive for human immunodeficiency virus (HIV) and is at increased risk for HIV encephalitis by HIV entry into the brain parenchyma\n13. Have a potential blood vessel-derived infection that can enter the brain parenchyma, resulting in meningitis or a brain abscess\n14. Carriers of the homozygosity apolipoprotein E allele (ApoE4), which is known to be associated with a thin blood-brain barrier.\n15. Pregnant or nursing women\n16. For women of childbearing potential\\* who agree to use a clinically appropriate method of birth control\\*\\* for the duration of the clinical trial\n\n    \\*Definition of women of childbearing age: means women who have experienced menarche, have not been surgically sterilized (hysterectomy or bilateral oophorectomy), or are not post-menopausal, defined as amenorrhea for 12 months or more for no other reason.\n\n    \\*\\*Clinically appropriate contraception: defined as \"\\[intrauterine device (e.g., Loop, Mirena), chemical barrier method (spermicide), or subdermal implantable contraceptive device (e.g., Implanon)\\] + physical barrier method (male or female)\" for women, tubal surgery, or laparoscopic contraception (a type of tubal ligation).\n17. Currently participating in another clinical trial or have participated in another clinical trial within 90 days of the screening date\n18. Other, if the investigator determines that participation in the clinical trial is inappropriate ethically or because it could affect the outcome of the clinical trial ☞ Specific reasons must be documented in the case report form.","50 Years","85 Years",{"count":438,"type":21},[58],"This clinical trial is designed to evaluate the initial safety and efficacy of opening the blood brain barrier (BBB) in patients with Alzheimer's disease using the ExAblate 4000 Type 2.1, a MR guided high-intensity focused ultrasound surgical device that disrupts brain tissue.",[513],"Alzheimer Disease",[515,288],"Blood Brain Barrier (BBB) Disruption","2024-08-20",{"date":518,"type":37},"2024-08-21",{"date":520,"type":21},"2024-09-01",{"date":522,"type":21},"2025-07-31",{"name":43,"class":44},{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":531,"targetDuration":533,"studyType":22,"phases":4,"briefSummary":534,"conditions":535,"keywords":539,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":222},"100546438","home-blood-pressure-variability-and-its-link-to-arteriosclerosis-and-metabolic-dysfunction-in-hypertensive-patients-100546438","NCT06394934","Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients","Impact of Home and Clinical Blood Pressure Variability on Arteriosclerosis and Metabolic Indicators","Inclusion Criteria:\n\n1. Adults aged 19 years or older.\n2. Diagnosed with hypertension.\n3. Regular use of antihypertensive medication for at least two years.\n4. Access to a home blood pressure monitor.\n5. Comprehensive medical records available for the past year.\n\nExclusion Criteria:\n\n1\\. Participants who are unable to consent or who might not reliably use the home monitoring app.",{"count":532,"type":21},4188,"3 Years","This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.",[61,536,537,538],"Blood Pressure Monitoring, Home","Arteriosclerosis","Metabolic Syndrome X",[540,541,542,537],"Home Blood Pressure Monitoring","Blood Pressure Variability","Pulse Wave Velocity","2024-04-28",{"date":545,"type":37},"2024-05-01",{"date":547,"type":37},"2024-01-09",{"date":549,"type":21},"2029-12-31",{"name":43,"class":44},{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":558,"targetDuration":560,"studyType":22,"phases":4,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":570,"locationsCount":109},"100497625","efficacy-and-safety-of-polymer-free-amphilimus-eluting-stent-according-to-the-diabetes-100497625","NCT05759676","Efficacy and Safety of Polymer-free Amphilimus-eluting Stent According to the Diabetes","A Prospective, Multicenter Observational Study of Efficacy and Safety of Polymer-free Amphilimus-eluting Stent (Cre8™\u002FCre8™ EVO) in Patients With Coronary Artery Disease According to the Presence of Diabetes Mellitus","Inclusion Criteria:\n\n* Age 19 or older\n\n  * Patients who agreed to the research protocol and clinical follow-up plan, voluntarily decided to participate in this study, and gave written consent to the consent form ③ Patients who underwent coronary angioplasty by inserting Cre8™ or Cre8™ EVO stent for coronary artery disease for a lesion confirmed within the last 1 month\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, amphilimus, cobalt chrome, stainless steel nickel, 316L metal, and contrast media If it can be controlled by pheniramine and pheniramine, registration is possible, but if there is known anaphylaxis, it is excluded.)\n\n  * Pregnant women, lactating women, or women of childbearing age who are planning to become pregnant during the study period ③ Patients who are planning surgery to stop antiplatelet drugs within 12 months from registration\n\n    * Patients whose remaining life expectancy is expected to be less than 1 year\n\n      * Patients who visited the hospital due to cardiogenic shock and are predicted to have a low survival rate based on medical judgment ⑥ Subjects participating in medical device randomization research ⑦ Patients who underwent surgery using a stent other than Cre8™\u002FCre8™ EVO at the time of registration",{"count":559,"type":21},1800,"12 Months","Drug-eluting stents (DES) have been found to reduce the rate of stent restenosis compared to bare metal stents (BMS), but the first generation DES caused an increase in stent thrombosis. The second generation DES, including the Cre8Evo stent, has been designed to address these issues. The Cre8Evo stent is made of cobalt chromium and releases the drug amphilimus into the vessel wall, which is quickly absorbed and then lost, creating a BMS-like form. The Cre8Evo stent does not contain polymers and does not induce an inflammatory response. It inhibits cdk2 and RhoA, reducing the proliferation and migration of vascular smooth muscle cells. In diabetic patients, the Cre8Evo stent showed superior results in suppressing late proliferation compared to conventional DES. The Cre8Evo stent has been found to be safe and effective in clinical studies, and it has a superior effect in the clinical course of diabetic patients compared to other stents. The purpose of the study is to evaluate the effectiveness and safety of the Cre8Evo stent in actual clinical practice, specifically comparing outcomes in patients with and without diabetes.",[563,263],"Diabetes Mellitus","2024-04-03",{"date":566,"type":37},"2024-04-04",{"date":568,"type":37},"2023-03-09",{"date":107,"type":21},{"name":43,"class":44},{"id":572,"slug":573,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":578,"targetDuration":533,"studyType":22,"phases":4,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":109},"100410043","korean-nirs-ivus-multicenter-registry-100410043","NCT04619355","Korean NIRS-IVUS Multicenter Registry","Korean Near-infrared Spectroscopy(NIRS)-Intravascular Ultrasound (IVUS) Multicenter Registry: a Comprehensive Study","Inclusion Criteria:\n\n* patient who underwent PCI using NIRS-IVUS\n* Subjects who agreed to the study plan and clinical follow-up plan, voluntarily decided to participate in this clinical study and agreed in writing to the subject consent form\n\nExclusion Criteria:\n\n* Subjects who cannot perform cardiovascular angiography due to severe symptoms of heart failure\n* Subjects whose expected life expectancy is within 1 year due to the accompanying disease\n* Women of childbearing age who plan to become pregnant within the study period",{"count":579,"type":21},1500,"Heart diseases known as the second cause of death in Koreans are coronary artery diseases such as angina and myocardial infarction. Coronary artery disease occurs when fat components, such as cholesterol, accumulate in the body. When these fat components are deposited in blood vessels, blood vessels' walls become thick, and the blood vessels narrow, which interferes with circulation. Without smooth circulation, the heart muscle does not function properly because the supply of oxygen and nutrient-rich blood, which is necessary for the heart to function normally, is not properly supplied. It leads to angina pectoris and chest pain and can cause myocardial infarction or even heart attack. Coronary artery disease in various aspects has a high mortality rate when it occurs in old age. The methods currently used for diagnosis and treatment are coronary angiography, percutaneous coronary intervention (PCI), and myocardial partial blood flow reserve history. There is a wide variety of tests (Fractional Flow Reserve, FFR), near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS).\n\nIn addition to the various aspects and treatment methods of this disease, treatment is often difficult, so the clinical significance is great. In the case of PCI, one of the methods of examination and treatment, the National Cardiovascular Data Registry (NCDR) has been established to establish guidelines for improving patient prognosis after surgery in the United States. NCDR, which started with the American College of Cardiology (ACC) initiative, is currently in an indispensable position for establishing clinical practice guidelines such as monitoring treatment-related indicators, quality improvement (QI), and clinical research. In charge. Besides, in recent years, the use of new drugs or new devices (Post-Market Surveillance), real-time risk estimation, and personalized planning is increasing.\n\nResearch to analyze the prognosis of various aspects of coronary artery disease, tests, and procedures has been constantly conducted, but comprehensive studies that can be used to improve the overall treatment are considered to be insufficient. At this point, a comprehensive study is required to establish clinical guidelines and to develop them continuously.\n\nIn particular, the area that needs research is whether or not future events can be prevented using vascular imaging. Studies have shown that if lipids are actively treated with statins, the lipid component of atherosclerotic plaques can be significantly reduced in just a few weeks. Suggests. According to the results of a YELLOW (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy) study published in 2012 based on a near-infrared spectroscopy-vascular ultrasound analysis, the active treatment group of statins showed the lipid-core burden index compared to the standard treatment group. ) showed a significant decrease.\n\nAccordingly, this study collects all comprehensive indicators such as test methods, test results, procedures, and treatment results for all patients undergoing near-infrared spectroscopy-vascular ultrasound treatment in Korea, including this institution, A comprehensive study of the disease registry related to the near-infrared spectroscopy-vascular ultrasound procedure is conducted to determine the type of disease, the number of affected vessels, and disease-related indicators.",[582],"Coronary Artery Disease With Myocardial Infarction",[584,585],"NIRS","IVUS",{"date":566,"type":37},{"date":588,"type":37},"2010-01-01",{"date":590,"type":21},"2027-05-01",{"name":43,"class":44},{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":56,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":4},"100534313","phase-2-genome-based-assessment-of-niraparib-zejula-efficacy-in-advanced-solid-tumors-with-homologous-recombination-deficiency-100534313","NCT06237205","Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency","Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)","Inclusion Criteria:\n\n1. Patient who agreed to participate in the KOSMOS-II master observation study.\n2. 19 years of age or older on the day of signing informed consent.\n3. Has a histologically- or cytologically-confirmed advanced (metastatic and\u002For unresectable) solid tumor.\n4. Has either known or suspected deleterious mutations in at least 1 of the genes involved in HRR or centrally confirmed HRD based on whole-genome sequencing (WGS).\n5. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n6. Has measurable disease per RECIST v1.1 as assessed by the local site investigator.\n7. Female participants of reproductive potential must agree to use contraception during the treatment period and for at least 6 months after the last dose. Male participants must agree to use contraception during the treatment period and for 90 days plus 5 X half-life after last dose.\n8. Has adequate organ function.\n9. Willing to provide biopsies from the tumor at screening to the central laboratory\n\nExclusion Criteria:\n\n1. Any previous exposure to PARP inhibitor\n2. Any other active malignancy or diagnosis of another malignancy within 2 years before study enrollment\n3. Has leptomeningeal metastases.\n4. Active central nervous system (CNS) lesions.\n5. Were resistant to prior platinum therapy (cisplatin, carboplatin, or oxaliplatin either as monotherapy or in combination) for advanced (metastatic and\u002For unresectable) solid tumor.\n6. Any cytotoxic chemotherapy from a previous treatment regimen within 14 days.\n7. Has received prior endocrine therapy as cancer treatment within 2 weeks prior to administration of study intervention.\n8. Has received palliative radiotherapy encompassing \\>20% of the bone marrow within 1 week of the first dose of study treatment.\n9. Has an active infection requiring systemic therapy.\n10. Has hypertension that cannot be adequately controlled with medication.\n11. Has active tuberculosis.\n12. Has active infection such as hepatitis B, hepatitis C\n13. Has a known history of Human Immunodeficiency Virus (HIV) infection.\n\n15\\) Impairment of gastrointestinal function or gastrointestinal disorders 16) Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of the Investigational product.\n\n17\\) Patients who do not consent to adequate contraception throughout the study period.\n\n18\\) Has a known hypersensitivity to the components of the investigational product or its analogs.\n\n19\\) Since this drug contains lactose, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.\n\n20\\) Since this drug contains Yellow No. 4 (Tartrazine), patients with a history of hypersensitivity or allergy to this ingredient.\n\n21\\) Medical, psychiatric, cognitive, or other conditions that may interfere with the ability of the subject to understand the subject information, provide the informed consent, follow the protocol process, or complete the clinical trial.\n\n22\\) The investigator judges that it is not appropriate to participate in this study for else reasons.",{"count":600,"type":21},33,[153],"Investigational Products: Niraparib Period: 3 years after IRB\u002FEC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing",[604],"Efficacy","2024-01-23",{"date":607,"type":37},"2024-02-01",{"date":609,"type":21},"2024-02-27",{"date":611,"type":21},"2027-06-30",{"name":43,"class":44},{"id":614,"slug":615,"hasResults":11,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":621,"enrollmentInfo":622,"targetDuration":4,"studyType":56,"phases":624,"briefSummary":625,"conditions":626,"keywords":629,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":638,"locationsCount":109},"100530479","phase-4-clinical-trial-to-evaluate-efficacy-and-safety-of-rivaroxaban-15mg-and-20mg-in-patients-with-non-valvular-atrial-fibrillation-100530479","NCT06187311","Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation","A Randomized, Open-labelled, Investigator-initiated Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation","REVISE-AF","Inclusion Criteria:\n\n1. adult men and women over 19 years of age when screening\n2. A person whose atrial fibrillation has been confirmed by electrocardiogram during screening and baseline.\n3. Anticoagulants for the prevention of stroke or systemic embolism For cases where medication is required, a person with a CHA2DS2-VASC score of 1 male\u002Ffemale 2 or more points (In case of one or more risk factors)\n4. 4\\) CrCl (Creatinine Clearance) ≥50 ml\u002Fmin\n5. A person who voluntarily agrees in writing to this study\n\nExclusion Criteria:\n\n1. Moderate mitral valve stenosis or mechanical artificial valve A person with a history of mechanical valve\n2. Thyroid disease, terminal hypertrophy, brown cytoplasm, adrenal glands that affect the occurrence of atrial fibrillation A person accompanied by cortical disease, parathyroid disease, pancreatic disease, etc.\n3. clinically significant bleeding (e.g., intracranial bleeding, gastrointestinal bleeding)\n4. Clinical significance of liver disease related to blood coagulation disorder and Child Pugh B and C liver disease associated with the risk of bleeding\n5. Patients with increased risk of bleeding due to the following conditions:\n\n   * Gastrointestinal ulcer history within 6 months prior to random allocation\n\n     * Intracranial or intracranial hemorrhage history within 6 months prior to random assignment\n\n       * vascular abnormalities in the spinal cord or brain\n\n         * History of brain, spinal cord or ophthalmic surgery within 30 days prior to random assignment\n\n           ⑤ Brain or spinal cord injury within 6 months prior to random allocation\n\n           ⑥ If you have esophageal varices or are suspected\n\n           ⑦ Arteriovenous malformations\n\n           ⑧ Vascular aneurysms\n\n           ⑨ Patients with malignant tumors (Neoplasm) at high risk of bleeding\n6. Stroke requiring combination of antiplatelet drugs when treating acute coronary syndrome or a patient with a history of transient ischemic attacks\n7. Patients who are overreacting to the main or components of Rivaroxaban\n8. Galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption a patient with genetic problems such as a disability\n9. Patients with uncontrolled hypertension (systolic BP \\> 180 mm Hg or diastolic BP \\> 100 mm Hg)","99 Years",{"count":623,"type":21},940,[260],"In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.\n\nIt is a randomized, open-label, and phase 4 clinical trial to compare and evaluate efficacy and safety of Rivaroxaban.\n\nAfter obtaining informed consent to participate in this trial, screening is performed (Screening visit).\n\nScreening includes baseline 12-lead electrocardiography and laboratory tests to exclude severe end-organ dysfunction (such as renal dysfunction, liver dysfunction, or anemia).\n\nBaseline visits are available on the same day. After screening, subjects eligible for the trial will be randomly assigned (1:1 ratio) to Group 1 (15 mg of Rivaroxaban) or Group 2 (20 mg of Rivaroxaban) (Baseline visit).\n\nThe study drug (Rivaroxaban 15mg or 20mg daily) will be administered for 12 months.\n\nDuring study period, a total of six visits (3,6,9,12 months) will be made, and follow-up test and outcome measurement will be done in each visit.",[627,628],"Atrial Fibrillation","Anticoagulant Adverse Reaction",[630,631],"Non-vitamin K antagonist oral anticoagulant","rivaroxaban","2023-12-31",{"date":634,"type":37},"2024-01-05",{"date":636,"type":37},"2023-01-12",{"date":611,"type":21},{"name":43,"class":44},""]